Research programme: cannabinoid-based therapeutics - Axim Biotechnologies

Drug Profile

Research programme: cannabinoid-based therapeutics - Axim Biotechnologies

Alternative Names: Cannabidiol/Gabapentin; Cannbleph™; MedChew-Dronabinol

Latest Information Update: 26 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Axim Biotech
  • Class Antiemetics; Appetite stimulants; Cannabinoids
  • Mechanism of Action Cannabinoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Restless legs syndrome
  • Research Anorexia; Attention-deficit hyperactivity disorder; Autistic disorder; Conjunctivitis; Nausea and vomiting; Post-traumatic stress disorders

Most Recent Events

  • 20 Jul 2017 Preclinical trials in Restless legs syndrome in Israel (PO)
  • 20 Jul 2017 Axim Biotechnologies plans a proof-of-concept phase II trial for Restless leg syndrome in Israel
  • 28 Mar 2017 Early research in Anorexia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top